Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic growth hormone-releasing hormone 1-29 analog
Sermorelin is a synthetic version of the first 29 amino acids of human growth hormone-releasing hormone. It was historically approved as Geref in a pediatric growth-failure context and can stimulate the pituitary to release endogenous growth hormone. Its direct evidence is mainly older pediatric and diagnostic research, not modern anti-aging, body-composition, sleep, recovery, or bodybuilding trials.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Sermorelin is a synthetic copy of the active first portion of the natural brain hormone that tells the pituitary gland to release growth hormone.
Researchers historically studied whether stimulating the body's own hormone release could help certain children with growth-hormone deficiency and assist diagnostic testing, instead of directly replacing growth hormone.
Older pediatric studies found increased growth speed in some children during the first treatment year. Direct comparisons generally found more consistent growth with recombinant growth hormone. The evidence is pediatric and product specific, not modern healthy-adult research.
Equivalence between historical Geref and current compounded products, adult body-composition or sleep effects, long-term metabolic and cardiovascular safety, and clinical benefit in healthy people remain unresolved. Historical schedules do not create a universal modern standard.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A multicenter historical study evaluated sermorelin-related GHRH(1-29) material in children with growth-hormone deficiency.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Pediatric growth and diagnostic studies exist; modern healthy-adult wellness outcomes have not been established.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Endogenous GH stimulation is documented, while popular adult anti-aging and body-composition claims remain unsupported.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The evidence is pediatric, historical, and focused on first-year growth speed rather than adult wellness outcomes. Historical material and procedures do not establish equivalence, reconstitution, or storage for current compounded products. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
The largest located pediatric program enrolled 110 children with growth hormone deficiency and reported increased mean height velocity during the first treatment year; comparative studies found somatropin generally produced greater or more consistent growth.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether any current compounded Sermorelin formulation is equivalent to historical Geref and whether repeated use in healthy adults has meaningful benefits or acceptable long-term metabolic, endocrine, cardiovascular, or neoplasia-related safety.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
It stimulates the pituitary GHRH receptor and depends on functional pituitary somatotrophs to release endogenous growth hormone.
That historical approval is real but narrow. It does not create an FDA-approved anti-aging, wellness, recovery, bodybuilding, sleep, or adult body-composition indication.
The largest located program reported a clear first-year increase in growth rate among eligible children.
Sermorelin stimulates endogenous secretion, whereas somatropin directly replaces recombinant GH. Those are different interventions with different evidence records.
Some people with hypothalamic GHRH deficiency can still release GH when the pituitary is directly stimulated.
The direct evidence base is primarily historical pediatric growth and diagnostic research.
Peptide identity, salt form, excipients, concentration, sterility, stability, and device instructions are formulation-specific.
Mechanisms
Sermorelin acetate is GHRH(1-29)-NH2, the bioactive N-terminal fragment of endogenous GHRH. It activates the pituitary GHRH receptor and therefore requires functional somatotroph reserve. Historical pediatric studies reported increased height velocity in some children with GH deficiency or idiopathic short stature, but responses were heterogeneous and comparative trials generally favored recombinant human growth hormone for stronger or more consistent catch-up growth. Diagnostic studies also showed that exogenous GHRH can reveal preserved pituitary reserve in people whose deficit may be hypothalamic. None of these findings establishes benefit, safety, pharmacokinetics, or product standards for modern compounded Sermorelin used for healthy aging or wellness.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Multicenter first-year treatment study
Children with growth hormone deficiency
Among 86 children eligible for efficacy analysis, mean height velocity increased from about 4.1 cm/year before treatment to 8.0 cm/year at six months and 7.2 cm/year at twelve months.
Study administration: Historical once-daily subcutaneous GHRH(1-29)-NH2 protocol; descriptive research context only
Limitations: This historical pediatric program does not establish benefit for adults, healthy aging, body composition, sleep, recovery, or modern compounded products. Final adult-height outcomes were not established.
Randomized three-arm comparison of two GHRH regimens and somatropin
60 children with hypothalamic growth hormone deficiency
Growth increased in all groups, but the somatropin group had substantially greater mean height velocity than either GHRH group.
Study administration: Two historical GHRH(1-29)-NH2 regimens or recombinant human growth hormone
Limitations: The study was short, pediatric, and used historical regimens. It supports a comparison boundary rather than a modern treatment recommendation.
Open-label one-year treatment study
18 prepubertal children with idiopathic short stature
Height velocity increased during treatment, followed by catch-down growth after treatment stopped. Fasting glucose, insulin, and IGF-1 increased during therapy.
Study administration: Historical twice-daily subcutaneous GHRH(1-29)-NH2 protocol
Limitations: Small uncontrolled pediatric study in children without classic GH deficiency. It cannot support adult wellness or anti-aging claims.
Sequential GHRH treatment followed by recombinant GH
Seven children with hypothalamic growth hormone deficiency
Most children had little or inconsistent growth response during GHRH treatment, while growth improved after switching to recombinant GH.
Study administration: Historical twice-daily subcutaneous GHRH(1-29)-NH2 followed by recombinant human growth hormone
Limitations: Very small, nonparallel comparison with historical formulations and schedules.
GH-response testing followed by longer-term GHRH treatment in selected children
Eight normal adults and 41 short children
Many children classified as GH deficient by conventional testing still released GH after GHRH, supporting a hypothalamic-versus-pituitary distinction in some cases.
Study administration: Intravenous GHRH testing and historical subcutaneous GHRH therapy
Limitations: Provocative-test interpretation is assay-, population-, and context-dependent. A response to GHRH does not establish a general indication for chronic use.
ClinicalTrials.gov term search
Population not stated.
Relay did not identify a modern registered Sermorelin program establishing adult anti-aging, body-composition, sleep, recovery, or general-wellness outcomes.
Study administration: Not stated in the current record.
Limitations: A registry search cannot prove that no unregistered or non-U.S. study exists, but it prevents historical pediatric evidence from being presented as a current adult development program.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryHistorically FDA approved as Geref in a pediatric growth-hormone-deficiency context; no FDA-approved anti-aging, wellness, bodybuilding, recovery, sleep, or adult body-composition indication Whether any current compounded Sermorelin formulation is equivalent to historical Geref and whether repeated use in healthy adults has meaningful benefits or acceptable long-term metabolic, endocrine, cardiovascular, or neoplasia-related safety.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2003-01-01 · PMID 14499707 · DOI 10.1016/S0169-409X(03)00109-1
1999-01-01 · PMID 18031173
1997-09-26
1996-06-01 · PMID 8772599
1994-01-01 · PMID 7955460 · DOI 10.1111/j.1365-2265.1994.tb02580.x
1993-01-01 · PMID 8329830 · DOI 10.1111/j.1651-2227.1993.tb12834.x
1989-01-01 · PMID 2537727 · DOI 10.1007/BF00595894
1987-01-01 · PMID 3111168